In short
The episode is a Bloomberg Businessweek Daily roundtable covering three threads: (1) U.S. Treasury market whiplash after a Treasury plan to affect the long end of the yield curve; (2) DOJ scrutiny of Mark Walter’s Guggenheim insurance business, including requests for records from credit rater Egan Jones; and (3) policy-driven relief in U.S. ground beef prices, plus a biotech segment on Moderna/Merck’s personalized mRNA melanoma vaccine.
Guests
Ira Jersey (Bloomberg Intelligence Chief U.S. Interest Rate Strategist) and Sarah Hunt (Alpine Saxon Woods Chief Market Strategist). Ava Benny Morrison (Bloomberg News senior legal reporter). Eilena Pang (Bloomberg News agriculture reporter). Vance Howard (Howard Capital Management CEO/portfolio manager; owns Barsi Ranch, Texas). Lisa Jarvis (Bloomberg Opinion biotech/pharma columnist).
Key claims/examples
Treasury action was “underwhelming”/mechanically unclear; possible “operation twist” risks if Fed later raises rates. DOJ seeks Egan Jones ratings tied to ~$20B restated insurer assets; Egan Jones rated at least ~1/5 of those assets. Trump’s 90-day tariff-free ground beef import up to 300,000 metric tons aims for 25% below market; supply-source uncertainty (Australia/Brazil/Argentina) and herd rebuilding limit impact. Moderna/Merck vaccine showed ~49% improvement vs Keytruda in recurrence/metastasis (phase 2), but melanoma may be “low-hanging fruit,” so broader cancer readouts are needed.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Chapters
Tap a time to open that second in VOMarket Whiplash and Treasury Focus
2:19 to 3:46
Discussion about the turbulent week in U.S. treasuries and market rates.
“Let's get to what has been the week of whiplash when it comes to U.S.”
Government Intervention and Market Liquidity
3:47 to 5:59
Analysis of how government actions affect market liquidity and investor confidence.
“I mean, Ira, where do you stand on this?”
Fed Strategy and Communication Challenges
6:00 to 8:10
Exploration of the Federal Reserve's strategy and communication issues with the market.
“compared to 30-year debt, which obviously takes 30 years to recapture that new interest rate environment.”
AI Investment and Credit Market Dynamics
8:11 to 11:42
Insights on how AI investments are impacting the credit market and treasury trades.
“He says that, hey, we want to give the reaction function.”
Introduction to the Investigation of Mark Walter
14:01 to 14:40
Learn about the ongoing investigation into Mark Walter's business practices and the implications for the market.
“There's a story that is definitely of great interest to the Bloomberg community, the market community, right?”
Insights from Ava Benny Morrison
14:40 to 16:29
Ava discusses the details of the DOJ's investigation and its focus on credit ratings.
“She's Bloomberg News senior legal reporter.”
Implications of Credit Ratings in Insurance
16:29 to 20:13
Explore how credit ratings affect insurance companies and the broader financial implications.
“I mean, look, I mean, they're approved, they're able to give credit ratings.”
Closing Thoughts from Ava
20:13 to 20:32
Ava shares her perspectives on the ongoing investigation and potential outcomes.
“It could take months, it could take weeks.”
Trump's Tariff Relief Announcement
20:32 to 20:50
Discussion on Trump's tariff relief for ground beef imports and its impact on prices.
“You're listening to the Bloomberg Business Week Daily Podcast.”
Analyzing Ground Beef Imports
20:50 to 21:54
Eilena Pang explains the significance of the president's announcement and the expected sources of beef imports.
“It's a key concern ahead of November midterm elections.”
Show all 21 chapters
Challenges in the Beef Industry
21:54 to 22:58
Examine the challenges faced by the beef industry amid tariff policy changes and supply issues.
“So he already tried to boost imports from Argentina, which for the first half of the year are about double what they were last year already.”
Rancher's Perspective on Market Dynamics
22:58 to 23:39
Rancher Vance Howard discusses the current state of the cattle market and policy impacts.
“And now we're in this really weird situation where U.S.”
Understanding Cattle Pricing and Policy Effects
23:39 to 25:52
Vance explains the complexities of cattle pricing in relation to tariffs and market conditions.
“We know that, but in addition to managing money, he owns and operates the Barsi Ranch in Madisonville, Texas.”
Food Production and Domestic Supply Issues
25:52 to 28:06
Discussion on the importance of domestic food production and the risks of importing livestock.
“You've got live cattle and you've got fully grown cattle.”
Concerns Over Food Supply Chain
28:06 to 29:12
Discusses the risks of relying on imported cattle and the state of domestic beef consumption.
“And not only that, Carol, when you expand on that, it's incredibly dangerous for us not to control our food supply.”
Market Insights from Vance Howard
29:12 to 30:21
Vance Howard shares insights on the beef market and consumer demand trends.
“Of course, yeah, be well, have a good weekend.”
Breakthrough in mRNA Technology
31:32 to 32:36
Discusses the significance of a new personalized vaccine for melanoma.
“You're listening to the Bloomberg Business Week Daily Podcast.”
Understanding the Vaccine's Impact
32:36 to 34:29
Explores the implications of the mRNA vaccine for treating melanoma and its broader potential.
“Yeah, I think it's actually two breakthroughs.”
Future of Personalized Cancer Treatments
34:29 to 37:53
Discussion on the future of personalized cancer vaccines and challenges in the field.
“efficacy because, you know, I guess we're just not used to hearing about vaccines as a treatment or something.”
Addressing Vaccination Skepticism
37:53 to 40:18
Talks about the challenges in changing public perception of mRNA technology.
“I feel like a lot of times in biotech and pharma, different companies start racing and competing.”
Wrap-Up with Lisa Jarvis
40:18 to 40:45
Concludes the discussion on the potential of mRNA technology in cancer treatment.
“Yeah, it does feel like I don't know, it does feel like a breakthrough, right in a lot of different ways.”
Transcript
Automatic transcript. May contain errors.0:00Carol Massar:Some people treat ChatGPT like some kind of smart search engine, and some use it to get work done. ChatGPT Work is a new way of working in ChatGPT that can take action across your apps and files, stay with a project for hours if needed, and turn a goal into finished work. It's designed to help you move from a chaotic starting point to a reviewable first version. So all the source materials, briefs, and scattered information that you have to grind through to turn into something useful can just become something useful. Put ChatGPT to work on your most ambitious ideas and projects. Get started at ChatGPT.com by selecting Work Mode, available on Plus and Pro plans.
0:42What it sounds like when you road trip to the iHeartRadio Music Festival in the all-new Hyundai Palisade Hybrid. Wow, this is really nice inside. The Palisade Hybrid has more luxury than ever. Whoa, this sound system is awesome. Turn it up. More tech than ever. Sweet. You got the available built-in dash cam? And more range than ever because the Palisade Hybrid gets up to 600 plus miles of range on a full tank. So do we ever have to stop for gas? Visit HyundaiUSA.com or call 562-314-4603 for more details. This is Jacob Goldstein from What's Your Problem? Running a business is hard enough. Don't make it harder with a dozen apps that don't talk to each other.
1:23One for sales, another for inventory, a separate one for accounting. That's software overload. Odoo is the all-in-one platform that replaces them all. CRM, accounting, inventory, e-commerce, HR. Fully integrated, easy to use, and built to grow with your business. Thousands have already made the switch. Why not you? Try Odoo for free at odoo.com. That's odoo.com.
2:18with Carol Masser and Tim Stenevek on Bloomberg Radio.
2:23Carol Massar:Let's get to what has been the week of whiplash when it comes to U.S. treasuries and really a focus on rates to around the globe. We've got a great roundtable. Ira Jersey, Bloomberg Intelligence, Chief U.S. Interest Rate Strategist, and Sarah Hunt, Chief Market Strategist at Alpine Saxon Woods, both here in studio. Traders are increasingly questioning what Treasury Secretary's next move will be after what's been, I think it's safe to say, a bit of a turbulent market, bond market, this past week. Sarah, how do you see it? I think that it was a surprise that he came out and said, this is what we're going to do in the long end of the curve.
3:00I think everyone's been looking at Warsh, Chairman Warsh, and looking at the Fed and seeing what's going to happen with interest rates there. I don't think that people were expecting the Treasury Secretary to come out and make his own news on this particular front. And I think there are, as you can see, quite a lot of questions about, one, one, how this is actually going to work mechanically, two, whether or not this is going to actually help the long end of the curve, which was arguably the idea because you've round-tripped that already. Because it did and didn't. It did and it didn't. And on the other hand, gold is just like, okay, we're gone.
3:27And it just is going again today. And I think that that's, you know, whether or not the only signal that gold gives is that we don't like anybody else's decisions or it's just a way to play a different angle, I think that you're seeing that reverse in interest rates didn't reverse gold. So that may be an anticipation of further movement.
3:44Carol Massar:Gold up 5 % this week. So yeah, we've seen a big move. I mean, Ira, where do you stand on this? Now that this is Friday, it's been a couple days. Yields are still moving up. Yeah, well, yields are kind of flattish, right? From the beginning of the week. So yeah, it did a whole lot of nothing. You know, devil is in the details here a little bit. So, you know, we won't find out the exact size. You know, he says maybe next week that they'll tell us more information. I did think it was really funny when Scott Besson said, you know, we're doing this because there's, you know, low liquidity in the middle of summer and things like that.
4:14But this doesn't start until September 9th. So I'm not exactly sure. That's technically the summer, right? I guess, but it's not August. It's not now. And in fairness, I was looking at the depth of the market, actually, right around the time that he said that. And actually, the depth of the market was not bad. The depth of the market was your typical summer-ish levels, not insanely low. So it's not like they really needed the direct liquidity support here.
4:39Carol Massar:I was going to say, political? Or did the market need this, Sarah? So it's interesting. I think that people have been concerned globally about rates rising, especially on the long end. And that's been a problem for investors. It's been a problem for all these companies that are now trying to finance the entire AI buildout. So the question is, are we doing something because this exact amount of money is going to make a change? Or is the fact that we're saying we're going to do something reminding everyone that the government can come in at any time and change the game? And I think it's a little bit to me of that.
5:08I don't know how you feel about that, Ira. But that was my take was a little bit like we're going to do something and not just stand there and let the market figure it out. Yeah, I think they did this and it was kind of underwhelming. Right. It's kind of like the Federal Reserve in December of 2007 when they did a, you know, they did a$40 billion program for a$300 billion problem. And, you know, so something like that. Maybe there will be a little bit more shock and awe. But there are risks to what they're doing, too. Right. Like if they're going to issue a whole lot of T-bills in order to buy back a lot of debt.
5:37And let's call this what it is. If it's going to work and if the president and Treasury secretary are really serious about getting long-end yields down, they have to do this in size. And we have to then call this an operation twist, similar to what the Treasury Department did in the 1960s. And if they do that, the one big risk for them is what happens if the Federal Reserve has to raise interest rates? because they're going to be issuing T-bills, which capture that interest rate move almost immediately compared to 30-year debt, which obviously takes 30 years to recapture that new interest rate environment.
6:10Sarah, what do you think it means for the Fed? Does this at all kind of alter when we do get a move from the Fed? I'm not sure what the answer to that is, and I don't know if there's any actual coordination going on that we don't know about. I mean, what we see is what the headlines are. We don't see what everybody's talking about behind the closed doors. So whether or not there is a conversation, I couldn't tell you. One would hope that there might be some sort of coordination or at least an understanding, because otherwise then you start to look like you've got government departments fighting one another.
6:40So what's your take on that? Well, I think that they're not coordinating, because if they were coordinating, then the Federal Reserve would not have stopped buying T-bills. The Federal Reserve was doing these reserve management purchases, buying$10 billion of T-bills every single month. So if they were coordinating and Treasury Secretary Besant said to Kevin Warsh, hey, we're going to be issuing more T-bills to buy 30-year debt. How about you buy some of those T-bills? Well, the Fed's not buying those T-bills. So if there was coordination, it was pretty poor.
7:07Carol Massar:Is this President Trump potentially too saying, hey, Scott Besant, I need you to do something because my Fed chair isn't doing something? Is it possibly? Absolutely possible, right? Because, again, I think we're all trying to understand, struggling to understand exactly what the point is in the timing frames. So fast forward. Okay. So do we get answers at Jackson Hole this coming week? I mean, we have a Fed chair who has already shown he doesn't like to say a lot or lay out the metrics of what metrics he is following and the Fed is following, the FOMC, in terms of figuring out monetary policy.
7:40Carol Massar:Do you think we're going to get anything this week? More specificity? He's told us he's going to frame the big questions. You can lay them out, but if you don't say what you're following, right? And this is the challenge that Kevin Worsh really has had. And I don't think he's done a particularly good job in communicating with the markets because you have to give the markets something, right? You can't give them nothing. And he's basically given the markets nothing. So he has to either say, give some kind of forward guidance or say, if this happens, then we will react this way. So give a reaction function.
8:08You have to do one of those two things. It's interesting because he put Mervyn King, former Bank of England governor, on the communications task force. This is what Murphy King wants to do. He says that, hey, we want to give the reaction function. We don't want to give forward guidance. But Kevin Warsh clearly has, if he read that paper, then he's not following it for sure. Well, and I also think that you're at the point now where you have to really look at that speech. If it was going to be under a microscope, now it's under five, right? Because now you went from, this is, we're all -
8:38Carol Massar:Every LLM is going to get that speech and we're going to get analysis. And everybody was focused on the Fed, and then they turned to the Treasury. So now they're extra focused on what they're going to say. And the fact that the communication has been, I would say, uneven is a word that you could use, doesn't help the situation. And I think that it makes it more important to clarify whatever. So I think Jackson Hole is, you know, we're all going to be sitting around on Friday watching what's going on. And we'll probably fall asleep because it won't be very interesting. But we're going to have to watch anyway.
9:06Well, we're going to be waiting for the walk, right? We're going to be waiting for all the central bankers.
9:10Carol Massar:Listen, Tom, Mike, and Lisa are going to be there. It's going to be interesting. Sarah, layer on top of this, and we've already talked with Ira about this, about the data center build-out. And you write in your notes, the pushback against data center build-out could be a blessing in disguise as well as investor concern over CapEx spending has been growing as the hyperscalers commit ever more equity and debt to the build-out. We've been talking about how the hyperscalers and everybody AI-related tapping credit markets and what that's done to maybe crowding out the treasury trade. What's top, like, what are, how worried are you about all of this tapping of the credit market for these AI guys?
9:44I think that there was definitely concern about how much money was being raised, how fast. And at the same time, you've got the government racing in to raise money. I mean, everyone's raising money, right? So that was an issue. Whether or not this money is actually going to have a return on investment is another question that people have been going crazy about. The idea that it's an arms race that you have to spend faster than China. The fact that there may be a bottleneck could be a blessing in disguise. just in the fact that people are worried so much about that spend and how much of that spend is coming out of debt and equity and no longer cash flow.
10:12And if that slows down, maybe that gives investors some room. Whether or not that becomes a further race to the top between China. I mean, I'm not sure how to look at that CapEx relative to other things. And I think that investors are struggling with that. Hey, join the crowd.
10:26Carol Massar:I don't know how to look at it either. Like, I feel like increasingly we say this, we see the headlines, we see the spend, and we're trying to put it in context. I also want to ask you about where equities go from here, especially if rates stay high. Because, like, we haven't really seen, I mean, even this week, like, it hasn't been a carnage in the S &P 500. But the 30-year yield is, you know, it's at these highs. Like, does this continue or is there really going to be some movement? Well, I sort of think that this is where Treasury came in and did something to the long end because that was starting to get investors worried.
10:59And you were seeing the S &P start to degrade. and the indices and other stocks underneath it as well, it's really going to be, it's a combination of it's going to be about earnings. And somebody made the point this morning, and I can't remember who it was. They were saying, yeah, earnings are great, but people are outspending those earnings. And that's a really good point because as we get into 2027, are we going to continue to up the ante on spend? And are the earnings going to follow? And I think that that's really, earnings is the biggest problem or benefit to the S &P. And right now that's all been working in everybody's favor.
11:31If that starts to trip and that second derivative starts to go, it doesn't even have to go down. It just has to grow less fast. And that becomes an issue unto itself, given where valuations are. Can we just keep going? This is really great. Come back next Friday? Sure. I'll be in Princeton. You'll be on vacation. I'll be on vacation. All right.
11:47Carol Massar:All right. Maybe a couple of weeks from now. Ira Jersey, thank you so much. Bloomberg Intelligence, Chief U.S. Interest Rate Strategist, and Sarah Hunt, Chief Market Strategist at Alpine Saxon Woods. Stay with us. More from Bloomberg Businessweek Daily coming up after this.
12:03Carol Massar:Some people treat ChatGPT like some kind of smart search engine, and some use it to get work done. ChatGPT Work is a new way of working in ChatGPT that can take action across your apps and files, stay with a project for hours if needed, and turn a goal into finished work. It's designed to help you move from a chaotic starting point to a reviewable first version. So all the source materials, briefs, and scattered information that you have to grind through to turn into something useful can just become something useful. Put ChatGPT to work on your most ambitious ideas and projects. Get started at ChatGPT.com by selecting Work Mode, available on Plus and Pro plans.
12:46What it sounds like when you road trip to the iHeartRadio Music Festival in the all-new Hyundai Palisade Hybrid. Wow, this is really nice inside. The Palisade Hybrid has more luxury than ever. Whoa, this sound system is awesome. Turn it up. More tech than ever. Sweet. You got the available built-in dash cam? And more range than ever because the Palisade Hybrid gets up to 600-plus miles of range on a full tank. So do we ever have to stop for gas? Visit HyundaiUSA.com or call 562-314-4603 for more details. Aging is real, and so are the benefits of. new Vital Proteins Collagen Sparkling Water because around the age of 30 your body needs backup to keep your collagen up so get your daily glow up now in three fresh flavors strawberry blossom, lemon lime and blood orange improved skin health in as little as 30 days thanks to collagen peptides cheers to that so you can stay vital, stay you visit vitalproteins.com to learn more and where to buy these statements have not been evaluated by the Food and Drug Administration this product is not intended to diagnose, treat, cure or prevent any disease You're listening to the Bloomberg Business Week Daily Podcast.
13:53Catch us live weekday afternoons from 2 to 5 Eastern. Listen on Apple CarPlay and Android Auto with the Bloomberg Business app.
14:01Carol Massar:Or watch us live on YouTube. There's a story that is definitely of great interest to the Bloomberg community, the market community, right? Yeah, it's all about the probe into the business of Guggenheim co-founder and CEO Mark Walter. Of course, he just sold off the L.A. Lakers and reports talks about other possible asset sales. And it's all about the insurance companies of Guggenheim. I feel like we keep learning more and more about the story, but it's wild. We did have a team of reporters finding out exclusively that the investigation into his businesses, his insurance business, has also led to the Department of Justice to a small but prolific credit rater.
14:38Carol Massar:So let's get to it. Here with the team's reporting and then one of the journalists on the story is Ava Benny Morrison. She's Bloomberg News senior legal reporter. She joins us here in New York City. Ava, thank you, thank you for coming on. We've been talking about this story a lot. Start with the investigation. Why is the Justice Department seeking records from Egan Jones? What do we need to understand about how this investigation continues to evolve and why they are all of a sudden this small, little-known maybe firm, but as we know a prolific credit rater is all of a sudden now a target or at least of interest for the DOJ?
15:15So a key part of this investigation is looking at how some of the insurance companies linked to Mark Walter made loans to affiliated parties. Originally, these transactions were marked as unaffiliated, but it's since turned out that the insurance businesses have had to restate$20 billion or so worth of these assets. And along with that, many of the assets have investment grade ratings from this credit rater called Egan Jones. So, what we've learned over the past few days in our reporting is that the DOJ is requesting information from Egan Jones about these ratings. So, they've asked for material related to Delaware Life and Clear Spring as well.
16:00This doesn't suggest that by any means that Egan Jones is a target, but sort of shows the wide net that prosecutors are casting to try and figure out how billions of dollars worth of loans from these insurers ended up being funneled out to affiliated parties. What does it signal when an insurance company is using a credit rating firm like Egan Jones? I mean, look, I mean, they're approved, they're able to give credit ratings. So it's not necessarily, you know, bad, but what can we learn about, you know, the fact that this company was working with this particular rating agency? Look, I think, you know, these insurance businesses were big clients for Egan Jones.
16:52I think from what we can gather, at least a fifth of the assets related to Mark Walters' insurance companies relied on Egan Jones ratings. So, I think it shows, you know, despite Egan Jones being a relatively small firm, it does play a really outsized role in rating a lot of the assets in the insurance industry, particularly at a time where Wall Street has really seized upon using policyholder funds for other investments. Right.
17:26Carol Massar:And as you guys remind us, an investment grade rating from a firm like Egan Jones can help lower the amount of capital that insurers must hold in case the assets sour. So allowing them to run essentially their businesses more efficiently. It's just kind of a good understanding. You know, Ava, we were talking about this after this story broke, and it's just this idea we saw during the mortgage meltdown and the 2008 crisis, that kind of somewhat cozy relationship, right, between ratings agencies and the companies that need those ratings. I'm not saying anything is untoward, but what are we hearing from the company, from the U.S.
18:08Carol Massar:Attorney's Office in Manhattan, from TWG Global? Like, what are they all saying about this? Look, I can definitely speak to the U.S. Attorney's Office in Manhattan because that is a key part of my beat. And, you know, we've heard from leadership over the past 12 months that they are very interested in what is happening in private credit. It's going up. It's going down. They're looking at how it's grown so quickly, whether marks are being applied correctly, and how the role of these third-party firms, what role they kind of play in assuring investors that this stuff that they're investing in is, in fact, investment-grade.
18:49And ratings agencies are one particular area that prosecutors have been very much interested in. Okay, so you're following this story. There's a lot of layers to this, you know, this kind of saga here. What is top of mind for you? What are you watching next as you continue to kind of report this out? Yeah, absolutely. So, I'm keeping a keen eye on how this all ends for Mark Walter. We've seen that he has started selling down some of his assets. So, for example, selling his stake in the Lakers recently, or agreeing to it at least. and, you know, seeing whether the, by the insurance companies saying that they're going to restate a lot of these transactions and some of these loans are going to be paid down, whether that's enough for regulators and for the DOJ to be satisfied with that as an outcome, or if the investigation continues at full throttle and we say, we see some kind of penalty for some of the players involved here.
19:56Carol Massar:How long might it take to get some kind of resolution about what's the next step forward here, especially on a legal basis, just quickly. Yeah, look, financial crime cases, investigations can take a very long time. We know this one has been going since at least the fall last year. So it's anyone's guess, really. It could take months, it could take weeks. We'll just have to watch and see. Yeah, it's very interesting. We know it's certainly something that's always top of mind for folks here on Wall Street and certainly those who read into the Bloomberg Terminal. Hey, Ava, thank you. We really appreciate it.
20:28Carol Massar:Ava Benny Morrison, Bloomberg News senior legal reporter, joining us there. You're listening to the Bloomberg Business Week Daily Podcast. Catch us live weekday afternoons from 2 to 5 Eastern. Listen on Apple CarPlay and Android Auto with the Bloomberg Business app. Or watch us live on YouTube. Well, President Trump said he would allow tariff relief for some ground beef imports and a bid to lower prices for American consumers. It's a key concern ahead of November midterm elections. We talked about it with our own Jeff Mason earlier in the 2 o 'clock hour. Here's what the president said, though, on Truth Social.
21:03Carol Massar:He said that for the next 90 days, the United States will allow up to 300 ,000 metric tons of product for ground beef to be imported with no out-of-quota tariff. The president went on to say, we have a commitment that this beef will be sold at 25 % below current market prices. I still feel like, and I think folks think, there are still more details to be known. What we do know, or what we don't know, is what we want to ask our next reporter. Eilena Pang is Bloomberg News agriculture reporter. She joins us on set. Eilena, you've been following what's been going on in beef prices. We've all moaned about the high cost.
Read the full transcript
21:39Carol Massar:What is significant about what we got from the president, or is there still stuff to be known? The biggest unknown, I think, is where the supplies are coming from. People are watching that really closely. I think the biggest bets are probably Australia, Brazil, Argentina. I think this move has been really interesting for the market because it's the latest in a series that Trump has tried to do. So he already tried to boost imports from Argentina, which for the first half of the year are about double what they were last year already. And soon the U.S. is expected to resume live cattle shipments from Mexico also to ease supplies.
22:15And so I think a move of the scope from the president really goes to show just how stubborn that pricing has been, that further action is needed. Okay, but, you know, when you think about it, if there's a cattle shortage, how much can tariff policy really help that? And realistically, what else can policymakers do to combat that? Yeah, it's a really hard situation for the industry. So what we see right now are really short-term Band-Aid fixes in terms of imports. They're very much helping to fill the shortfall in demand, but the U.S. net produces most of its beef already on its own. So imports, even as they're rising to a record share, record share is still sub-20%.
22:58And now we're in this really weird situation where U.S. ranchers are trying to rebuild the herd, but that takes a long time. So basically the calculus they're trying to do is, do I sell my animal for me right now and get really high prices back? Or do I wait to keep that animal for breeding later on? And it's been really hard to do that. And when you see this type of move, the live cattle futures market plummeted today. So that's another move that's creating uncertainty for ranchers even more.
23:29Carol Massar:Well, we happen to have a rancher with us. We are delighted to have back with us. He joined us earlier in the week, Vance Howard. He's CEO and portfolio manager of Howard Capital Management. We know that, but in addition to managing money, he owns and operates the Barsi Ranch in Madisonville, Texas. They do specialize in registered long-porn cattle. We want to bring you into the conversation that we're having here. Vance, what do we need to understand about this business and what we're seeing in terms of policy out of the White House? Well, you know, they've kind of gotten themselves in a little bit of a pinch because, you know, we do have a shortage of cattle right now.
24:04You know, if you look at Tyson, they shut down two meatpacking plants about two weeks ago, one in Illinois, one in Utah for lack of supply. I mean, they don't have the cattle to deal with. And you've got two different kinds of cattle.
24:18Carol Massar:All right. A little bit of a freeze there. We'll see if we can get back to Vance. You know, Eileen, I want to go back to you. You follow this sector. We talked about on the weekend with you about what Tyson has been doing because they just don't have the cattle, so they don't need the plants up and running. Yeah, exactly. The meat packers have been in a situation for basically since the start of 2024 where they've been paying so much for cattle that they're losing money on every head that they process. And so they've gradually, Tyson, JBS, Cargill, they've all sort of pulled back capacity a little bit to try to ease that competition for supplies.
24:51To be sure, the companies are still profitable, but that's largely in their other segments like chicken. The beef business itself is losing money. and Tyson having already closed plants this time around reported earnings again that again missed the mark cut their outlook and they're right sizing more.
25:10Carol Massar:Vance I think we've reconnected with you maybe there was a cattle listening and a cow or something and I got a little maybe they put a tariff on me. Exactly maybe so so continue with your thought in terms of understanding the broader cattle market because it isn't just been tariffs there's been other things that have been impacting the supply? Well, it has been. And, you know, when you look at the high cost of cattle right now, where there's a lot of ranchers that want to sell at this high. So, you know, building back up the supply over 90 days may be more of a challenge than what people realize.
25:38And what you're seeing with ground beef is different than what you're seeing with prime. Prime is at the fourth highest price it's ever been in history, which is, you know, way up there. Now, ground beef has dropped down quite a bit. But then again, you've got to look at the different kind of cattle. You've got live cattle and you've got fully grown cattle. Live cattle is about a four to 800 pound calf or a steer. So that's a little bit cheaper. It's not a fully cow that's going to deliver the most amount of beef. But I think there's a lot of challenges here. And with the tariffs coming off, I think it benefits Canada.
26:07But I also think it can benefit us, too, as far as dropping down some of these costs. You know, I own two restaurants, too. And our cost of prime steaks are through the roof. Okay, but over the long term, do those kind of downward price pressures continue from this tariff relief, or do we need to see more? Well, I think you're going to have to see more. I don't think 90 days is going to put a dent in anything. And I mean, you know, a cow's got to breed. It's got to deliver a calf. It's got to grow up to the point that it can be eaten. I mean, you can see my rug back there. We ate that guy. And so that's a cowhide back there.
26:44But it's going to take time to redo this. And again, with high prices of cattle, especially prime, you know, you're seeing a lot of ranchers that are selling off. But hey, here's one thing. And Carol and I talked about this last week when I was in New York. You know, we've got Elon Musk coming in with a semiconductor plant, which is buying up thousands of acres around Grimes County in between College Station and Huntsville. We're in a rural part of Texas with a lot of ranchers. Well, as he buys these ranch lands up, that's driving up the cost of land, which is, you know, a lot of ranchers are selling into that profit margin.
27:12So that's also going to increase the profitability factor. Is a cow profitable if your land's real expensive anymore? So there's a lot of different dynamics going on here.
27:23Carol Massar:So great for you guys who own the land, perhaps, but not necessarily great for we consumers? That's exactly right. You know, I've got a good friend of mine, a good business partner. He's getting bought out by Elon Musk right now. I think he might have signed the contract last week for that semiconductor plant going into Grimes County. And they paid him a premium price to where he said, I can't I cannot not take it. You know, I just got to say just one last question, Vance. You know, it makes me think about the food production, like when we're competing for things like data centers or what have you or semiconductor plants.
27:54Carol Massar:I mean, you got to have places to produce food. And increasingly, we want to make sure we have production domestically, because if anything, COVID taught us supply chains can be impacted pretty quickly. And not only that, Carol, when you expand on that, it's incredibly dangerous for us not to control our food supply. That's not a good thing either. And by the way, when you import cattle from different countries, you know, I know the FDA does their job, but, you know, they're eating what they're feeding them down there. And so who knows what that is? On our ranch, we raise grass-fed cattle with no preservatives, no additives, and we try to stay away from any type of chemicals because we're trying to eat healthy down here.
28:30But, you know, who knows what you're getting sometimes when you're getting some beef from overseas.
28:34Carol Massar:Eilina, last thought from you in terms of as you watch this market. I think we're starting to see interesting cues on the demand side that Carol and I talked about recently. The July 4th period is peak demand grilling season. And we sort of started seeing consumers become a little bit more hesitant. Not necessarily demand destruction. Like, they're still buying it. But they're saying we're not willing to keep buying more if it's at these prices. and, you know, economics 101 curve, either demand will have to come down or the supply will have to come back up from a significant herd rebuild. And I think everyone's sort of watching to see which one will key first.
29:12Carol Massar:All right, well, great stuff as always. Vance Howard, thank you so much. Double duty in the last week. Really appreciate it. Of course, yeah, be well, have a good weekend. Vance Howard, CEO and Portfolio Manager of Howard Capital Management. He owns and operates the Barsi Ranch in Madisonville, Texas. specializing in registered longhorn cattle and our own Eilena Peng, also doing double duty for us when it comes to what's going on in the beef market. She's Bloomberg News agricultural reporter. Stay with us. More from Bloomberg Businessweek Daily coming up after this.
29:46Carol Massar:Some people treat ChatGPT like some kind of smart search engine, and some use it to get work done. ChatGPT work is a new way of working in ChatGPT that can take action across your apps and files, stay with a project for hours if needed, and turn a goal into finished work. It's designed to help you move from a chaotic starting point to a reviewable first version. So all the source materials, briefs, and scattered information that you have to grind through to turn into something useful can just become something useful. Put ChatGPT to work on your most ambitious ideas and projects. Get started at ChachiPT.com by selecting Work Mode.
30:26Carol Massar:Available on Plus and Pro plans. What it sounds like when you road trip to the iHeartRadio Music Festival in the all-new Hyundai Palisade Hybrid. Wow, this is really nice inside. The Palisade Hybrid has more luxury than ever. Whoa, this sound system is awesome. Turn it up. More tech than ever. Sweet, you got the available built-in dash cam? And more range than ever because the Palisade Hybrid gets up to 600-plus miles of range on a full tank. So do we ever have to stop for gas? Visit HyundaiUSA.com or call 562-314-4603 for more details. Aging is real, and so are the benefits of new Vital Proteins Collagen Sparkling Water.
31:07Because around the age of 30, your body needs backup to keep your collagen up. So get your daily glow up, now in three fresh flavors. Strawberry blossom, lemon lime, and blood orange. Improved skin health in as little as 30 days thanks to collagen peptides? Cheers to that. So you can stay vital, stay you. Visit VitalProteins.com to learn more and where to buy. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. You're listening to the Bloomberg Business Week Daily Podcast. Catch us live weekday afternoons from 2 to 5 Eastern.
31:39Listen on Apple CarPlay and Android Auto with the Bloomberg Business App.
31:43Carol Massar:Or watch us live on YouTube. We want to kind of get to it because the excitement was over this personalized vaccine developed by Moderna and Merck. We mentioned it with the team in TV that reduced the recurrence of melanoma in a large late stage trial, raising expectations for treating the deadliest form of skin cancer. That's important, but it also provided the strongest evidence yet that messenger RNA technology will have a successful second act. It leads us to a Bloomberg opinion piece that caught our attention. Yeah. And on why this vaccine may be a marvel. So it's Lisa Jarvis. She's a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry.
32:22Previously, she was executive editor of Chemical and Engineering News. Lisa, thanks for joining us. Just talk to us about the significance of could we call it a breakthrough here in mRNA technology? Yeah, I think it's actually two breakthroughs. One for mRNA technology because we have not seen in a large stage trial an mRNA-based therapy succeed in cancer. And it's also a breakthrough when it comes to personalized cancer vaccines in general. That's something people have been trying to work towards for decades. The idea has been around for literally more than a century, but biotech companies have been working on it for several decades.
33:08And so to have a late stage trial offer concrete evidence that this idea of using our own immune system, priming it in order to fight cancer itself works is a big deal.
33:21Carol Massar:Yeah, it's kind of interesting. I feel like Lisa, we've been talking about this for a while, right? And really utilizing the body to figure out how to fight serious diseases or whether it's cancer. I mean, a big step forward. What else has to be done though? Because there was so much investor enthusiasm this week over it, especially in particular for Moderna. Yeah, I mean, I think step one is for all of us to see the full results from this study. So we're going to want to see the details to understand the magnitude of the benefit. But I think the much bigger deal is that melanoma, though this is a huge advance, melanoma is kind of considered a low-hanging fruit when it comes to cancer.
34:04Skin cancers have a lot of mutations that make it easier for immune cells to see them. And so we want to know that this is going to work outside of that. And certainly Merck and Moderna have a number of trials going in lung cancer, bladder cancer, kidney cancer to prove that that's possible. But, you know, we're going to have to wait for the readouts to know, you know, whether this is a broadly applicable advance. And okay, remind us the results that we've gotten so far about the efficacy because, you know, I guess we're just not used to hearing about vaccines as a treatment or something. Yeah.
34:39So I think, I think one thing that can be hard to wrap our mind around is that with the vaccine, you're actually at this stage trying to keep the cancer from coming back. So you're teaching your immune system, not just to beat down the cancer right now, but far into the future so that it kind of recognizes what a cancer cell looks like. So we don't have the numbers on this phase three trial, but we do have numbers from a smaller phase two trial that was long lasting. It looked out over five years and showed that for both recurrence of cancer and for these distant metastases, so the cancer spreading to other parts of the body, it was an improvement of 49 % over Keytruda, which is Merck's very effective cancer immunotherapy on its own.
35:22So that's a very big advance. And I'll just note, as I did in my column, that Keytruda had already really changed the paradigm when it came to melanoma. And so to do better than that by this much is why people are so excited.
35:39Carol Massar:Yeah, I think about, you know, we've learned so much in terms of how to dealing with problems or with the heart. Right. But cancer continues to be a really tricky health care problem. I mean, there's Alzheimer's. There's other things, too, as well. But I just think about it because cancer can impact people differently. Right. And so and bodies can can impact it. I've seen people with stage three or stage four who come back and then there are others who don't. So it's just interesting. but this idea of kind of personalizing, but it is still also, what's interesting is it's a double treatment, right?
36:15Carol Massar:I mean, that's what's interesting as well. Right. I mean, I think, well, I think one of the things that we have an advantage here is that you can really personalize this and Mark and Moderna are doing that. So they take a patient's own tumor and they sequence it and And then they use AI to find the mutations that are probably the most likely driving their cancer and for our immune system to respond to. And the idea is just like when we get a regular vaccine that, you know, it's going to combat the cancer now, which the Keytruda is helping. But that also it's giving our immune cells these kind of mug shots, you know, when the enemy comes back that we want to shut down and that it can roar into action, which has really been difficult.
37:00We have a lot of treatments that work very well in the short term, but not aren't curative, aren't giving people a lot of years where they're not anxious about, you know, a recurrence, which is which is difficult.
37:11Carol Massar:Right. Recurrence are spreading elsewhere. So, right. If you could shut it down, you think about what that would do for people's outlook and their ability to survive this longer, much longer term. Yeah, and I think even just their quality of life, being able to make decisions in the longer term without having that kind of constant worry. You know, we have to see the data. We have to know how long it's lasting. But I think this is so exciting because it changes the way that we treat cancer, you know. And it could really be meaningful for a lot of people, especially if it works outside of melanoma.
37:46And that is not to diminish the accomplishment in melanoma, which does affect, you know, over 100 ,000 people in the U.S. each year. So what else do we need to watch for? I feel like a lot of times in biotech and pharma, different companies start racing and competing. Are there other companies trying to do what Moderna is doing right now? Yeah, I mean, BioNTech, which is the other company that we all came to know during COVID because they had partnered with Pfizer on their vaccine. They've been working on this, like Merck, since before the pandemic. We've got smaller companies that are working on it as well.
38:20I think one thing that we really should be advocating for at this point is more investment. I mean, this should be encouraging us to go all in because we know that it's a concept that finally has been proven. There has been some cutbacks when it comes to research and mRNA. And so I think, you know, trying to really put the foot on the pedal so that we can get to a place where these are reality. Now, I'll just say to you, like these trials, these late stage trials take time. I think we're going to see some more readouts coming up in other types of cancers that will give us the first hint of, you know, what our expectations should be when it comes to mRNA vaccines potential in treating cancer broadly.
39:03Carol Massar:Yeah, and I think about some of those tricky cancers having had pancreatic in my family, my husband's family. I mean, it's a terrible cancer, and maybe this provides a way of really tackling that one, because really once it is diagnosed, there's not a lot of hope for the individuals. One of the things I want to ask you, though, Lisa, before we wrap up here, you end the story saying, the other question hanging over this otherwise good news is whether it will convince them any medical science skeptics and conspiracy theorists that messenger RNA isn't so nefarious after all. We saw that coming out of COVID, right?
39:37Carol Massar:About, oh, wait, is this going to alter your genetic material? And there are other things that came out of it. Just remind us, and does something like this maybe change how the scientific community and the community overall look at messenger RNA? I mean, I certainly hope so. It's a fleeting effect in our body. It's a vaccine. It's showing you something in the short term. It's not changing your DNA. And so I hope it's convincing. And, you know, who can tell? But I hope that the people that were very worried and the skeptics and conspiracy theorists who may have a family member that really could benefit from something like this, you know, open their minds a little bit and see that, you know, it's a technology we're supporting.
40:22We really need to make the investment.
40:24Carol Massar:Yeah, it does feel like I don't know, it does feel like a breakthrough, right in a lot of different ways. And I'm excited to kind of see where the research goes from here. Lisa, thanks so much. I'm glad we could bring you bring everybody your column, especially after week where we saw certainly investors taking note of this move from Moderna. Lisa Jarvis. Thank you. This is the Bloomberg Businessweek Daily podcast available on Apple, Spotify and anywhere else you get your podcasts. Listen live weekday afternoons from 2 to 5 p.m. Eastern on Bloomberg.com, the iHeartRadio app, TuneIn, and the Bloomberg Business app.
41:02You can also watch us live every weekday on YouTube and always on the Bloomberg Terminal.
41:15What it sounds like when you road trip to the iHeartRadio Music Festival in the all-new Hyundai Palisade Hybrid. Wow, this is really nice inside. The Palisade Hybrid has more luxury than ever. Whoa, this sound system is awesome. Turn it up. More tech than ever. Sweet, you got the available built-in dash cam? And more range than ever because the Palisade Hybrid gets up to 600 plus miles of range on a full tank. So do we ever have to stop for gas? Visit HyundaiUSA.com or call 562-314-4603 for more details. This is Jacob Goldstein from What's Your Problem? Running a business is hard enough. Don't make it harder with a dozen apps that don't talk to each other.
41:56One for sales, another for inventory, a separate one for accounting. That's software overload. Odoo is the all-in-one platform that replaces them all. CRM, accounting, inventory, e-commerce, HR. Fully integrated, easy to use, and built to grow with your business. Thousands have already made the switch. Why not you? Try Odoo for free at O-D-O-O dot com. That's Odoo dot com.
42:46stay you. Visit vitalproteins.com to learn more and where to buy. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
From the publisher
The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF
After a turbulent stretch for the US bond market, traders are heading into the weekend with questions about what Treasury Secretary Scott Bessent’s next move will be. Treasuries slipped Friday, led by the short end, after data showed business activity grew at its fastest pace in more than four years, backing the case for interest-rate hikes. Bloomberg Intelligence's Ira Jersey and Alpine Saxon Woods' Sarah Hunt break down the weeks' moves, and the impact of Bessent's intervention.
On today's episode:
- Ira Jersey, Bloomberg Intelligence Chief US Interest Rate Strategist & Sarah Hunt Alpine Saxon Woods Chief Market Strategist
- Ava Benny-Morrison, Bloomberg News Senior Legal Reporter
- Ilena Peng, Bloomberg News Agriculture Report & Vance Howard, Howard Capital Management CEO & Portfolio Manager
- Lisa Jarvis, Bloomberg Opinion Columnist
See omnystudio.com/listener for privacy information.
